Biologics in combination with nonbiologics: efficacy and safety

Dermatologic Therapy
William G Stebbins, Mark Lebwohl

Abstract

The mechanisms of action of biologic therapies differ from the currently used systemic therapies by attacking specific steps in the pathogenesis pathway of psoriasis. Preliminary data show that combination therapy using biologics may allow for improved therapeutic efficacy with fewer side effects, including decreased risk of hepatotoxicity and nephrotoxicity commonly associated with the most widely used systemic agents, methotrexate, and cyclosporine. However, some concerns have been raised regarding the increased immunosuppression, increased risk of infection, potential for development of certain types of malignancy, as well as the significant increased cost of therapy. Both potential benefits and toxicities of combination therapy will be reviewed here. Long-term clinical studies are warranted to more accurately quantify the risks and benefits associated with combination therapy. The role of combination therapy will continue to be refined over the next few years to maximize its potential in the treatment of resistant psoriasis.

References

Nov 1, 1978·The Journal of Investigative Dermatology·J R BjerkeR Matre
Oct 1, 1992·Journal of the American Academy of Dermatology·J J Schwartz, P L Myskowski
Apr 1, 1991·Journal of the American Academy of Dermatology·N J LoweR Armstrong
Oct 1, 1989·Journal of Autoimmunity·I T Cockburn, P Krupp
May 1, 1987·The British Journal of Dermatology·J M GommansB E van Huystee
Jan 1, 1987·Transplantation·I Penn
Aug 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J N BavinckB J Vermeer
Mar 1, 1993·Journal of the American Academy of Dermatology·P Duhra
Nov 1, 1996·Journal of the American Academy of Dermatology·N J LoweM T Grabie
Mar 31, 1998·Journal of the American Academy of Dermatology·H H RoenigkM Lebwohl
Apr 29, 1998·Journal of the European Academy of Dermatology and Venereology : JEADV·G E GibsonG M Murphy
May 13, 1998·Klinische Monatsblätter für Augenheilkunde·C Cursiefen, L M Holbach
Sep 17, 1998·Journal of the American Academy of Dermatology·M LebwohlG Weinstein
Mar 13, 1999·Annals of Internal Medicine·L W MorelandM E Weinblatt
May 6, 1999·The New England Journal of Medicine·D H PresentS J van Deventer
Aug 25, 1999·Journal of the American Academy of Dermatology·M Lebwohl
Sep 1, 1999·The British Journal of Dermatology·C M ClarkC E Griffiths
Dec 22, 1999·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·T SrivastavaB A Warady
Nov 30, 2000·The New England Journal of Medicine·P E LipskyUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
Dec 21, 2000·The British Journal of Dermatology·F CainelliS Vento
Apr 9, 2001·The New England Journal of Medicine·F J Fernández-Fernández, P Sesma
Jun 29, 2001·Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie·R B Cohen, K A Dittrich
Jul 27, 2001·The American Journal of Gastroenterology·W A StackC J Hawkey
Sep 25, 2001·Journal of the American Academy of Dermatology·M LebwohlP McClelland
Oct 13, 2001·The New England Journal of Medicine·J KeaneM M Braun
Dec 12, 2001·PharmacoEconomics·M J NuijtenM Koopmanschap
Feb 14, 2002·The British Journal of Dermatology·S IyerN J Lowe
Feb 22, 2002·The New England Journal of Medicine·Wei Shen LimI D Johnston
Mar 15, 2002·The New England Journal of Medicine·Jonathan MyersJ Edwin Atwood
May 16, 2002·Blood·Xavier MarietteUNKNOWN Investigators of the Club Rhumatismes et Inflammation
Jul 26, 2002·American Journal of Ophthalmology·Claus CursiefenLeonard M Holbach
Oct 31, 2002·The Medical Journal of Australia·Irwin G S Lim, James V Bertouch
Dec 7, 2002·European Journal of Gastroenterology & Hepatology·Daniel HelblingMartin Krause
Mar 15, 2003·Rheumatic Diseases Clinics of North America·Barry Bresnihan, Gaye Cunnane

❮ Previous
Next ❯

Citations

Jan 25, 2008·Dermatology : International Journal for Clinical and Investigative Dermatology·Esra AdişenMehmet Ali Gürer
Nov 7, 2014·American Journal of Clinical Dermatology·Jennifer C Cather, Jeffrey J Crowley
Sep 23, 2010·Actas dermo-sifiliográficas·G CarreteroUNKNOWN Grupo de Psoriasis de la AEDV
Nov 26, 2009·Journal of the American Academy of Dermatology·David M RosmarinUNKNOWN National Psoriasis Foundation
Apr 25, 2009·Journal of the American Academy of Dermatology·Robert E KalbMark Lebwohl
Oct 2, 2007·Dermatologic Clinics·Yalçin TüzünRonni Wolf
Apr 14, 2007·Dermatologic Clinics·Alpesh DesaiJames Q Del Rosso
May 15, 2009·Clinical and Experimental Dermatology·L PavlovskyD Mimouni
Jul 22, 2008·The Australasian Journal of Dermatology·Ana LucasIsabel Betlloch
Jan 24, 2008·Journal of the European Academy of Dermatology and Venereology : JEADV·P Gisondi, G Girolomoni
Feb 21, 2006·Journal of the American Academy of Dermatology·Paul S Yamauchi, Nicholas J Lowe
Jun 13, 2006·The Journal of Dermatological Treatment·Jared ConleySteven R Feldman
Jun 13, 2006·The Journal of Dermatological Treatment·Sarah G Hodulik, Joshua A Zeichner
Jan 25, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·N Usmani, C Wilson
Oct 1, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·E CampolmiA Cossidente
May 20, 2005·Seminars in Cutaneous Medicine and Surgery·Kevin R SteinSteven R Feldman
May 20, 2005·Seminars in Cutaneous Medicine and Surgery·Jennifer Clay Cather, Alan Menter
Sep 1, 2010·Actas dermo-sifiliográficas·G CarreteroUNKNOWN Grupo de Psoriasis de la AEDV

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.